Last Price
189.64
Today's Change
-0.82 (0.43%)
Day's Change
189.30 - 191.62
Trading Volume
913,781
Market Cap
335 Billion
Shares Outstanding
1 Billion
Avg Volume
4,744,948
Avg Price (50 Days)
194.32
Avg Price (200 Days)
176.12
PE Ratio
63.46
EPS
2.99
Earnings Announcement
30-Oct-2024
Previous Close
190.46
Open
190.54
Day's Range
189.3047 - 191.62
Year Range
135.85 - 199.95
Trading Volume
917,643
1 Day Change
-0.37%
5 Day Change
-2.69%
1 Month Change
-1.91%
3 Month Change
8.26%
6 Month Change
15.53%
Ytd Change
18.73%
1 Year Change
27.20%
3 Year Change
76.63%
5 Year Change
152.53%
10 Year Change
255.54%
Max Change
442.14%
No result.
Sector: Healthcare - Healthcare
Industry: Drug Manufacturers—General
Description:
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.